1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsK99AI196249: Glycosylation as a Host Defense Strategy for Multiple Alphaviruses is sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Investigates the role of glycosylation in host defense mechanisms against alphaviruses.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
To gain access to cells, most viruses attach to receptor molecules. While many virus receptors have been identified, the impact of post-translational modifications on receptor function remains understudied. Glycosylation is a major type of post-translational modification of cell surface proteins, and viruses often exploit cell surface glycans for entry.
However, given the extreme heterogeneity of glycosylation, it is unlikely that all glycans play equivalent roles in host-virus interactions. This proposal posits that specific glycosylation patterns can disrupt virus-receptor interactions, serving as a host defense mechanism against viral entry.
My preliminary studies identify β1,3-N-acetylglucosaminyltransferase 2 (B3GNT2) as an interferon-stimulated gene that strongly inhibits multiple alphaviruses, including Venezuelan equine encephalitis virus (VEEV). B3GNT2 catalyzes the biosynthesis of poly-N-acetyllactosamine (polyLacNAc) chains leading to heavy and bulky glycosylation of LDLRAD3, a host receptor for VEEV.
Consistent with its role in receptor glycosylation, B3GNT2 reduces VEEV attachment to the cell surface. Based on these findings, I hypothesize that B3GNT2 inhibits VEEV entry by glycosylating the viral receptor and may protect against VEEV-induced pathogenesis in vivo.
Given its broad antiviral effects against multiple alphaviruses, I further hypothesize that B3GNT2 inhibits other alphaviruses including Chikungunya virus (CHIKV), through a similar mechanism.
In the K99 mentored phase, I will integrate biochemical, cell biological, and glycan-based approaches to define the antiviral mechanism of B3GNT2 against VEEV (Aim 1) and investigate its antiviral role in VEEV pathogenesis using mouse models (Aim 2).
In the R00 phase, I will extend these studies to CHIKV infection in B3gnt2 knockout mice and define the role of polyLacNAc glycosylation in blocking receptor-mediated entry of multiple alphaviruses (Aim 3). These studies will provide key insight into how host cells prevent viral entry through glycosylation and establish experimental tools to explore the broader role of glycosylation in host-pathogen interactions.
Project Number: 1K99AI196249-01 | Fiscal Year: 2026 | NIH Institute/Center: National Institute of Allergy and Infectious Diseases (NIAID) | Principal Investigator: Sung-Yeon Hwang | Institution: UT SOUTHWESTERN MEDICAL CENTER, DALLAS, TX | Award Amount: $149,035 | Activity Code: K99 | Study Section: Special Emphasis Panel[ZRG1 IIDA-J (81)] View on NIH RePORTER: https://reporter. nih. gov/project-details/11282596
According to the current listing, eligibility includes: Nonprofits, Universities, State/local governments, Individuals. Confirm the full requirements in the official notice before applying.
K99AI196249: Glycosylation as a Host Defense Strategy for Multiple Alphaviruses is funded by National Institute of Allergy and Infectious Diseases (NIAID). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articleThe ReVAMPP network funds vaccine and monoclonal antibody research across five virus families. Here is who won, what the prototype-pathogen strategy means, and how to position for the next round.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article